Format

Send to:

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9.

Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Collaborators (248)

Brophy M, Duckworth W, Davis S, Emanuele N, Fried L, Hostetter T, McCullough P, O'Connor T, Palevsky P, Peduzzi P, Pfeffer M, Seliger S, Sinnott P, Star R, Toto R, Warren S, Zhang J, Fried L, Emanuele N, Duckworth W, Brophy M, Conner T, Guarino P, McCullough P, O'Connor T, Peduzzi P, Seliger S, Warren S, Zhang J, Berl T, Himmelfarb J, Tuttle K, Verter J, Woolson R, Servilla K, Thomas G, McQuade C, Bernauer M, Seliger S, Fink J, Luck J, Parsa A, Fink W, Scism B, Brown J, Purohit N, Jones T, Reddy C, Natarajan L, Lopez R, Durr J, Kaufman J, Cxypoliski R, Hamburger T, Lohr J, Cloen D, Arora P, Ranjan R, Lopes-Virella M, Pittman C, Caulder S, Soule J, Miller R, Julius M, Zhao J, Kern E, Watts J, Drawz P, Othersen J, Rosansky S, Reynolds J, Peterson A, Smith B, Neumann T, Duffy C, Talmor L, Warner R, Reilly R, Jain N, Wadsworth M, Mehta P, Penfield J, Elsayed E, Muzina R, Kourany W, Gitter K, Patel U, Cooney S, Zimering M, DeMarco C, Shin J, Rosenberg F, Sama A, Quinn S, Martinez E, Tantravahi J, Leehey D, Emanuele N, Linnerud P, Agrawal L, Lteif A, Moore K, Walsh J, Dixon B, Moss L, Franzwa B, Wallace W, Goel A, Hurst A, Wiegmann T, Somers D, Michaels R, Price V, Krause M, Satter E, McMillan J, Peterson M, Jaipaul N, Firek A, Sadjadi S, Fernando R, Simpson V, Ding G, Wadie M, Hawley A, Kato J, Gunneman T, Christiansen H, Blakely P, Wall B, Madison J, Cooke C, Naseer A, Huch K, Mangold T, Perumareddi P, Ma K, Kollman L, Rust J, Slinin Y, Ikizler A, Egbert P, Booker C, Davis D, Hung A, Davis S, Harper P, Venkatarman A, Blumenthal S, Yug B, Hussain S, Anderson R, Gerety M, Dunning D, Vogel M, Wagstaff S, Chadwell T, DeSouza C, Ludwig S, Lit Y, Gorodetskaya I, Meyer T, Baker P, Orozco L, Plummer E, Collier S, Herb C, Reaven P, Ramkumar M, Hartwig K, Homer M, Rao R, Sonel E, Dailey A, Lea D, Watnick S, Walczyk J, Johnston T, Zieve F, Kimmel M, Frederickson S, Levy J, Tarkington P, Larrick L, Weiler L, Clark S, Grimsdale A, Gopalakrishnan R, Conwill L, Clark E, Rauchman M, Giddings S, Felton S, Benabe J, Serrano-Rodriguez J, Mercado Z, Vidal-Cardona A, Arroyo L, Melendez A, Santiago L, Padilla B, Lamarche J, Peguero A, Reinhard R, Courville C, Hozo A, Thomas C, Crowley S, Zelas C, Murphy M, Peixoto A, Federman D, Churak J, Joncas C, Perez I, Fried L, Overberger P, Emanuele N, Milks L, Duckworth W, Christenson R, Rebuck H, Guarino P, Antonelli M, Chiu S, Dellert K, Hunter B, Joncas C, McBride V, O'Connor T, Peduzzi P, Sayers D, Smith J, Zhang J, Sather M, Conner T, Day J, Warren S, Haakenson C, Krueger D, Brophy M, Humphries D, Govan D, Cockroft J, Bobra S, Baylosis A, Nuckles L, O'Leary T.

Erratum in

  • N Engl J Med. 2014;158:A7255.

Abstract

BACKGROUND:

Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).

PMID:
24206457
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk